ABT/ACHN/Medivir— does anyone take the success of ABT-450, the PI, as part of this combo as bearish for the other 2nd gen HCV PI candidates such as those from Medivir and ACHN?
No—if anything, I would say it’s modestly bullish for the other second-generation PI’s.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”